About Aldeyra Therapeutics, Inc.
https://www.aldeyra.comAldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis.
CEO
Todd C. Brady
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 64
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
KNOLL CAPITAL MANAGEMENT, LLC
Shares:5.48M
Value:$23.22M
PERCEPTIVE ADVISORS LLC
Shares:5.22M
Value:$22.14M
BLACKROCK, INC.
Shares:3.8M
Value:$16.13M
Summary
Showing Top 3 of 155
About Aldeyra Therapeutics, Inc.
https://www.aldeyra.comAldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $8M ▼ | $-7.69M ▲ | 0% | $-0.13 ▲ | $-7.15M ▲ |
| Q2-2025 | $0 | $10.17M ▼ | $-9.77M ▲ | 0% | $-0.16 ▲ | $-9.23M ▲ |
| Q1-2025 | $0 | $10.43M ▼ | $-9.93M ▲ | 0% | $-0.17 ▲ | $-9.39M ▲ |
| Q4-2024 | $0 | $16.51M ▲ | $-15.81M ▼ | 0% | $-0.27 ▼ | $-15.27M ▼ |
| Q3-2024 | $0 | $16.14M | $-15.11M | 0% | $-0.25 | $-14.57M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $75.3M ▼ | $77.8M ▼ | $28.56M ▼ | $49.24M ▼ |
| Q2-2025 | $81.92M ▼ | $84.96M ▼ | $29.67M ▲ | $55.29M ▼ |
| Q1-2025 | $90.06M ▼ | $93.2M ▼ | $29.6M ▼ | $63.6M ▼ |
| Q4-2024 | $101.15M ▼ | $104.61M ▼ | $33.6M ▲ | $71M ▼ |
| Q3-2024 | $112.74M | $117.32M | $32.22M | $85.1M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-7.69M ▲ | $-7.02M ▲ | $25M ▲ | $120.75K ▲ | $18.1M ▲ | $-7.02M ▲ |
| Q2-2025 | $-9.77M ▲ | $-8.56M ▲ | $-554.13K ▼ | $0 ▼ | $-9.11M ▼ | $-8.56M ▲ |
| Q1-2025 | $-9.93M ▲ | $-12.47M ▼ | $7.29M ▲ | $1M ▲ | $-4.18M ▲ | $-12.47M ▼ |
| Q4-2024 | $-15.81M ▼ | $-12.04M ▼ | $-1.56M ▼ | $7.78K ▲ | $-13.59M ▼ | $-12.04M ▼ |
| Q3-2024 | $-15.11M | $-7.97M | $5.26M | $-197.39K | $-2.91M | $-7.97M |
CEO
Todd C. Brady
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 64
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
KNOLL CAPITAL MANAGEMENT, LLC
Shares:5.48M
Value:$23.22M
PERCEPTIVE ADVISORS LLC
Shares:5.22M
Value:$22.14M
BLACKROCK, INC.
Shares:3.8M
Value:$16.13M
Summary
Showing Top 3 of 155